Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?

Ramesh Mazhari
Judith Hsia
Division of Cardiology, George Washington University, Washington, DC, USA

Abstract: Peripheral arterial disease (PAD), like coronary heart disease, is a clinical manifestation of atherosclerosis and is associated with increased mortality. Although atherosclerotic cardiovascular disease is the leading cause of death for women as well as for men, PAD in women has received less attention than coronary heart disease or stroke. This paper reviews the prevalence of PAD, its risk factors, clinical significance, and management in women. One gender-specific therapeutic issue of particular interest to practitioners and the lay public is the role of postmenopausal hormone therapy. Prior to completion of the Heart and Estrogen/Progestin Replacement Study and the Women’s Health Initiative Hormone Trials, postmenopausal hormone therapy was believed to exert antiatherosclerotic effects and to thereby reduce coronary heart disease risk in women on the basis of case-control and cohort studies. This review particularly focuses on the role, if any, of postmenopausal hormone therapy for prevention or treatment of PAD, which was a pre-specified secondary outcome for these three randomized trials.

Keywords: women, estrogen, peripheral arterial disease

Introduction
Atherosclerotic peripheral arterial disease (PAD) can be categorized as aortic or involving arterial beds supplying the lower extremities, upper extremities, brain, or viscera such as the kidneys or intestine. This review will focus on lower extremity disease in women with particular focus on the role of postmenopausal hormone therapy.

Diagnosis
The prevalence of PAD varies with its definition and with approaches to screening. Clinical diagnosis of PAD is traditionally made by history of claudication or absent or diminished pulses. The Rose questionnaire (Rose et al 1982), which has been widely used to screen for claudication, will not detect asymptomatic disease. The ratio of ankle systolic blood pressure to arm systolic blood pressure at rest, the so-called ankle-brachial index, is an inexpensive approach to screening for asymptomatic PAD (Table 1) and can be accurately conducted in the primary care setting (Raines et al 2004). An ankle-brachial index of \( \leq 0.90 \) has been reported to have 90% sensitivity and 98% specificity for arterial stenosis \( \geq 50\% \) (Greenland et al 2000).

In the Rotterdam Study, 36 (5%) of 742 women with ankle-brachial index < 0.9 reported claudication on the Rose questionnaire (Meijer et al 1998). Symptoms of
Interventional Radiology recommends ankle-brachial index (American Diabetes Association 2004). The Society of index be considered in all patients with type 2 diabetes foot care include a recommendation that ankle-brachial American Diabetes Association guidelines for preventive party payers, including Medicare in the United States. Nonetheless, the procedure is not reimbursed by many third- magnetic resonance angiography (Greenland et al 2000). associated with imaging studies such as ultrasound or overall diagnostic accuracy without incurring the expense but poor sensitivity. Ankle-brachial index provides excellent approach for detection of PAD provides high specificity, or men (18/2135, 0.8%) with normal ankle-brachial indices. Claudication was reported by few women (15/3023, 0.5%) of men with ankle-brachial index < 0.9, 37 of 424 (9%). Prevalence of PAD depends upon the characteristics of the population studied and the definition of PAD used. The Framingham Offspring Study defined PAD as ankle-brachial index < 0.9 and identified it in 3.9% of 1554 men and 3.3% of 1759 women in their predominantly white cohort (Murabito 2002). A recent assessment of PAD prevalence was conducted by the National Health and Nutrition Examination Survey (NHANES), which measured ankle-brachial index in a probability sample of 2381 United States residents over the age of 40 years from 1999–2000 (Gregg 2004). Oversampling of the elderly, low-income persons, non-Hispanic blacks, and Mexican Americans was undertaken to permit more reliable estimates in these subpopulations. In NHANES, the prevalence of PAD, defined as ankle-brachial index < 0.90 in either leg, was 4.3% (95% confidence interval [CI] 3.1%–5.5%). Peripheral arterial disease was identified with similar frequency in men (4.5%, 95% CI 2.8%–5.6%) and women (4.2%, 95% CI 2.9%–6.1%) and increased with age. Extrapolating from the random NHANES sample to the United States’ population, approximately 5 million adults, half of them women, have abnormal ankle-brachial indices.

### Clinical significance of peripheral arterial disease

Both symptomatic and asymptomatic PAD predict functional decline (McDermott 2004). Annual decline in 6-minute walk performance was more marked among asymptomatic patients with ankle-brachial index < 0.9 (~77 feet, 95% CI –135 to –19 feet) than among healthy...
controls (−9 feet, 95% CI −37 to +20 feet; p = 0.04). Annual decline was even greater among patients with abnormal ankle-brachial index and claudication (−111 feet, 95% CI −173 to −50 feet; p = 0.004).

A small minority of patients with PAD will develop critical leg ischemia over 5 years (~5%), with 1%–4% progressing to amputation (Faxon 2004). In addition to the impact of lower extremity atherosclerosis on downstream tissue, PAD may be considered a general marker of atherosclerosis; angiographic coronary disease is identified in about 85%; and carotid stenosis, defined as >30% by ultrasonography, is identified in about 60% of patients with PAD (Faxon 2004).

The presence of PAD has prognostic significance both for coronary heart disease and death (Criqui 1992; Hooi 2004). Criqui et al (1992) followed 565 men and women prospectively for 10 years. Among the 33 women with PAD identified by either ankle-brachial index or Doppler ultrasound, 33% died during follow up, compared with 26 of 225 (12%) of women without PAD. After multivariate adjustment, the relative risk for all-cause mortality was 3.1 (95% CI 1.9–4.9) for individuals with prevalent PAD. Relative risk for coronary death was 6.6 (95% CI 2.9–14.9).

The relationship between low ankle-brachial index and cardiovascular disease was confirmed in the Cardiovascular Health Study, a population-based cohort that included 3282 women aged ≥65 years (Newman 1999). Among individuals without prevalent cardiovascular disease at baseline, the hazard ratio in multivariate-adjusted Cox proportional hazards models was 1.40 (95% CI 0.90–2.17) for myocardial infarction, 1.12 (95% CI 0.74–1.70) for stroke, and 2.03 (95% CI 1.22–3.37) for cardiovascular death (Newman 1999).

The stroke risk with low ankle-brachial index was stronger in the Framingham Heart Study, in an analysis carried out when study participants’ mean age was 80 years (Murabito 2003). In multivariate-adjusted Cox proportional hazards analysis, the hazard ratio for stroke was 2.0 (95% CI 1.1–2.7) among individuals with ankle-brachial index <0.9. The incidence of stroke was about 1.7% per year in this analysis, compared with 0.6% per year in the Cardiovascular Health Study (Newman 1999).

The relationship between ankle-brachial index and stroke was also examined in the Atherosclerosis Risk in Communities Study, which included 2450 black and 5776 white women, aged 45–64 years (Tsai 2001). The incidence of stroke was low among women in this middle-aged cohort, 0.2% per year. In Cox proportional hazards analysis adjusted for age, race, gender, center, blood pressure, diabetes, smoking, cholesterol, and prevalent coronary heart disease, ankle-brachial index did predict stroke risk (p-value for trend 0.03).

Thus, epidemiologic data from a variety of cohort studies strongly supports the relationship between low ankle-brachial index and increased risk of myocardial infarction, stroke, and death.

**Peripheral arterial disease risk factors**

Risk factors associated with PAD are similar to those of other atherosclerotic diseases. In NHANES, multivariate-adjusted logistic regression models identified current smoking as the strongest predictor of abnormal ankle-brachial index (odds ratio [OR] 4.23, 95% CI 1.95–9.17) (Gregg 2004). Other independent predictors of PAD included diabetes mellitus (OR 2.08, 95% CI 1.01–4.30), total cholesterol ≥240 mg/dL (OR 1.67, 95% CI 1.01–2.74), glomerular filtration rate <60 mL/min/1.73 m² (OR 2.17, 95% CI 1.10–4.30), and non-Hispanic black ethnicity (OR 2.39, 95% CI 1.11–5.12). Overweight (body mass index 25–30 kg/m²) and obese individuals (body mass index >30 kg/m²) were less likely to have abnormal ankle-brachial index, OR 0.87 and 0.54, respectively, compared with normal weight individuals (referent), although body mass index was not an independent determinant of abnormal ankle-brachial index.

Risk factors for PAD in women were assessed in the Heart and Estrogen/Progestin Replacement Study (Hsia 2000), a cohort of 2763 postmenopausal women with coronary heart disease. Independent predictors of peripheral arterial revascularization or amputation among women assigned to placebo for 4.1 years included hypertension (relative risk 2.66, 95% CI 1.60–4.44) and diabetes (relative risk 1.98, 95% CI 1.27–3.11). Negative predictors in Cox proportional hazards models included body mass index (relative risk 0.70, 95% CI 0.56–0.88) and high-density lipoprotein cholesterol (relative risk 0.76, 95% CI 0.60–0.96).

The relationship between chronic kidney disease and PAD has been identified in both a random sample of United States residents and in a cohort of women with coronary heart disease (O’Hare, Glidden, et al 2004; O’Hare, Vittinghoff, et al 2004). In the Heart and Estrogen/Progestin Replacement Study, the rate of lower extremity revascularization or amputation was inversely related to creatinine clearance. After multivariate adjustment, the relative risk among women with creatinine clearance
30–59 mL/min/1.73 m² was 1.63 (95% CI 1.04–2.54) compared with women with creatinine clearance ≥60 mL/min/1.73 m² (referent). Among women with creatinine clearance <30 mL/min/1.73 m², relative risk was 3.24 (95% CI 1.20–8.78) (O’Hare, Vittinghoff, et al 2004).

**Treatment**

Peripheral arterial disease is a marker of systemic atherosclerosis; consequently, aggressive management of conventional atherosclerotic risk factors should be undertaken, especially smoking cessation. Exercise is also an important component of clinical management in patients with lower extremity arterial atherosclerosis (Menard 2004); supervised exercise, even once weekly, appears to improve long-term outcomes compared with exercise advice alone (Cheetham 2004). Potential mechanisms underlying the benefits of exercise training include improved oxygen extraction and utilization, better walking biomechanics, enhancement of collateral blood flow, favorable effects on endothelial function, arterial compliance, free radical formation, and inflammation (Stewart 2002; Falcone 2003).

Pharmacologic interventions can: (1) improve claudication symptoms; (2) reduce cardiovascular events in patients with PAD; or (3) reduce incident peripheral arterial events in individuals with or without PAD at baseline. Gender-specific data is generally not available, so these agents are briefly summarized. The one therapeutic area specifically studied in women is the role of postmenopausal hormone therapy, which is discussed in more detail.

**Lipid-lowering agents**

A secondary analysis of the Scandinavian Simvastatin Survival Study, a cohort of 4444 coronary heart disease patients including 827 women, identified new or worsening intermittent claudication in 2.3% of participants assigned to simvastatin 40 mg daily compared with 3.6% of those assigned to placebo during median follow up of 5.4 years, a relative risk of 0.62 (95% CI 0.44–0.88) (Pederson 1998).

Both simvastatin (Aronow 2003; Mondillo 2003) and atorvastatin (Mohler 2003) have been evaluated in patients with claudication. In a group of 86 patients with claudication and hypercholesterolemia randomized to simvastatin 40 mg or placebo for 6 months, pain-free walking distance was increased by simvastatin (+90 meters, 95% CI 64–116 meters, p<0.005) (Mondillo 2003). In a trial of 354 patients with claudication, including 81 women (23%) randomized to atorvastatin 10 mg, atorvastatin 80 mg, or placebo for 12 months, pain-free walking time improved by 63% (91 ± 15 seconds) in the atorvastatin 80 mg group compared with 38% (39 ± 8 seconds) in the placebo group (p=0.025) (Mohler 2003). Although quality of life measures did not differ among treatment groups, the combined atorvastatin groups had significantly fewer clinical peripheral vascular events (2 events in the atorvastatin 80 mg group, 1 in the atorvastatin 10 mg group, 9 in the placebo group, p=0.003).

**Angiotensin-converting enzyme (ACE) inhibitors**

Ramipril reduced cardiovascular events in patients with peripheral vascular disease in the Heart Outcomes Prevention Evaluation trial, which randomized 9297 high-risk patients (2480 women) to ramipril or placebo for 4.5 years (Yusuf 2000). Among women enrolled, 49.4% had PAD at baseline defined as claudication, >50% stenosis by angiography, prior peripheral revascularization, or ankle-brachial index <0.9. In women, ramipril reduced the primary end point (myocardial infarction, stroke, or cardiovascular death) from 14.9% to 11.3% (relative risk 0.77, 95% CI 0.62–0.96) (Lonn 2002).

**Antiplatelet agents**

Aspirin, clopidogrel, and ticlopidine have all been demonstrated to reduce cardiovascular events in patients with PAD, but gender-specific analyses are lacking. In meta-analysis of patients with PAD, aspirin reduced the OR for major vascular events from 7.1% to 5.8% (p<0.004) (Antithrombotic Trialists’ Collaboration 2003).

The Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events trial randomized 19 185 patients with cardiovascular disease, including 6452 with PAD at baseline, to clopidogrel 75 mg daily or aspirin 325 mg daily for a mean of 1.9 years (CAPRIE Steering Committee 1996). Among those with PAD at study entry, the primary outcome (stroke, myocardial infarction, or vascular death) was identified in 3.7% per year in the clopidogrel group vs 4.9% per year in the aspirin group, an adjusted risk reduction of 23.8% (95% CI 8.9%–36.2%).

Although ticlopidine has also been shown to reduce coronary and cerebrovascular events in patients with claudication (relative risk reduction 0.66, 95% CI 0.45–0.96) (Janzon 1990), this agent is not widely used because of gastrointestinal symptoms, neutropenia, and thrombotic thrombocytopenic purpura.
Postmenopausal hormone therapy

During the two years preceding menopause, women’s low-density lipoprotein cholesterol rises by 10%, high-density lipoprotein cholesterol falls by 6%, and triglycerides rise by 11% (Jensen 1990). Until recently, postmenopausal hormone therapy, which ameliorates these unfavorable lipid changes (The Writing Group for the PEPI Trial 1995), was believed to prevent atherosclerosis.

The association of postmenopausal hormone therapy with ankle-brachial index was studied in a population-based observational study of 2196 Dutch women, aged 55–80 years (Westendorp 2000). Recent postmenopausal hormone use was reported by 31 women and remote use by 320 women. Duration of therapy ranged from 1 to more than 15 years; 9% of hormone users had taken progestin in addition to estrogen. Ankle-brachial index < 0.9 was identified in 284 women (13%). In logistic regression analyses adjusted for age, smoking, and education, women who reported using postmenopausal hormones for at least one year were less likely to have abnormal ankle-brachial index (relative risk 0.48, 95% CI 0.24–0.85) compared with never users (referent). When short- and long-term hormone users were combined, relative risk of abnormal ankle-brachial index was 0.65 (95% CI 0.44–0.98).

Other observational studies found that women taking postmenopausal estrogen had less severe carotid atherosclerosis, assessed by ultrasound (Jonas 1996; Le Gal 2003). Recent randomized trials of postmenopausal hormone therapy have underscored the limitations of observational studies in evaluating the risks and benefits of estrogen. Peripheral arterial disease has been less intensively studied than coronary heart disease or stroke, but some data is available from randomized trials.

In one randomized trial using an intermediate outcome of change in intima-medial thickness assessed by ultrasound, unopposed estradiol reduced progression of carotid disease (Hodis 2001). Another trial, using combination estrogen with progestin found no effect on progression of ultrasonographic carotid atherosclerosis (Byington 2002).

Three large randomized trials with clinical end points have now assessed the impact of postmenopausal hormone therapy on clinical cardiovascular end points, with PAD as a prespecified secondary outcome. The Heart and Estrogen/Progestin Replacement Study randomized 2763 women with documented coronary heart disease to conjugated estrogens (6.25 mg daily) with continuous medroxyprogesterone acetate (2.5 mg daily) or to placebo. Peripheral arterial disease, assessed as peripheral arterial revascularization or amputation, was a prespecified secondary outcome. During 4.1 years of follow up, 143 lower extremity arterial events were identified, 77 among women assigned to placebo, and 66 in women assigned to conjugated estrogens with progestin (Hsia 2000). The age-adjusted relative risk for lower extremity events with combination hormone therapy was 0.88 (95% CI 0.58–1.35); multivariate-adjusted relative risk was 0.85 (95% CI 0.56–1.31).

For all types of PAD (aortic, carotid, and lower extremity), the relative hazard with combination estrogen/progestin was 0.87 (95% CI 0.66–1.44); the annual incidence of peripheral arterial events was 2.9%. Independent predictors of peripheral arterial events differed in the two treatment groups; among placebo recipients, hypertension and diabetes were positive determinants, whereas high-density lipoprotein cholesterol and body mass index were negative determinants of incident peripheral arterial events. In contrast, among women assigned to combination hormone therapy, diabetes and current smoking were positive predictors of peripheral arterial events. The observed potentiation by estrogen/progestin of the adverse effects of smoking (p-value for interaction = 0.03) may parallel the increased risk of myocardial infarction among oral contraceptive users (Lewis 1996) and provides an argument against prescribing postmenopausal hormones to smokers.

In The Women’s Health Initiative Estrogen Plus Progestin Trial, 16608 generally healthy postmenopausal women with intact uterus were randomly assigned to conjugated estrogens (6.25 mg daily) with continuous medroxyprogesterone acetate (2.5 mg daily) or to placebo – the same regimen as the Heart and Estrogen/Progestin Replacement Study. During 5.6 years of follow up, the incidence of peripheral arterial events, defined as overnight hospitalization for either peripheral arterial symptoms or intervention, was low (0.14% per year), reflecting the overall healthy condition of trial participants. The hazard ratio for lower extremity events with combination estrogen/progestin was 1.07 (95% CI 0.62–1.84) (Hsia 2004). For all peripheral arterial events (including aortic and carotid disease), the hazard ratio was 0.89 (95% CI 0.63–1.25). Subgroup analysis did not identify any characteristics associated with particularly high- or low-risk of PAD with combination hormone therapy.

The Women’s Health Initiative Estrogen Alone Trial randomized 10 739 women with prior hysterectomy with
conjugated estrogens (0.625 mg/daily) or to placebo (The Women’s Health Initiative Steering Committee 2004). Analyses of peripheral arterial events in that trial have not yet been completed. The coronary risk with unopposed estrogen (hazard ratio 0.91, 95% CI 0.75–1.12) appears to differ from that with combination estrogen/progestin (hazard ratio 1.24, nominal 95% CI 1.00–1.54) (Manson 2003). Whether the risk of peripheral arterial events with unopposed estrogen differs from that with combination estrogen/progestin remains to be seen.

**Summary**

Lower extremity PAD occurs with similar frequency in men and women. Among women with abnormal ankle-brachial index, 95% will not report claudication. Consequently, non-invasive screening, such as measuring the ankle-brachial index, is appropriate in asymptomatic individuals with atherosclerotic risk factors. Clinical management of lower extremity arterial disease should include physical training, optimally with supervised exercise, and aggressive treatment of conventional atherosclerotic risk factors. The increased coronary and cerebrovascular risk in individuals with PAD appears to be attenuated by ACE inhibition and clopidogrel.

Postmenopausal hormone therapy with combination estrogen/progestin provides no protection against peripheral arterial events. The role of unopposed estrogen for prevention of PAD remains to be determined.

**References**

American Diabetes Association. 2004. American Diabetes Association: clinical practice recommendations. Preventive foot care in diabetes. *Diabetes Care*, 27:563–4.

Antithrombotic Trials’ Collaboration. 2002. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*, 324:71–86.

Aronow WS, Nayak D, Woodworth S, et al. 2003. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and one year after treatment. *Am J Cardiol*, 92:711–12.

Byington RP, Furberg CD, Herrington DM, et al; Heart and Estrogen/Progestin Replacement Study Research Group. 2002. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. *Arterioscler Thromb Vasc Biol*, 22:1692–7.

CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*, 348:1329–39.

Cheetham DR, Burgess L, Ellis M, et al. 2004. Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomized trial. *Eur J Vasc Endovasc Surg*, 27:17–23.

Criqui MH, Langer RD, Fronck A, et al. 1992. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med*, 326:381–6.

Falcone RA, Hirsch AT, Regensteiner JG, et al. 2003. Peripheral arterial disease rehabilitation: a review. *J Cardiopulm Rehabil*, 23:170–5.

Faxon DP, Creager MA, Smith SC Jr, et al; American Heart Association. 2004. Atherosclerotic Vascular Disease Conference: executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. *Circulation*, 109:2595–604.

Greenland P, Abrams J, Aurigemma GP, et al. 2000. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III, *Circulation*, 101:E16–22.

Gregg EW, Sorlie P, Paulosse-Ram R, et al. 2004. Prevalence of lower-extremity disease in the US adult population 20–40 years of age with and without diabetes: 1999–2000 National Health and Nutrition Examination Survey, *Diabetes Care*, 27:1591–7.

Hodis HN, Mack WJ, Lobo RA, et al; Estrogen in the Prevention of Atherosclerosis Trial Research Group. 2001. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med*, 135:939–53.

Hooi JD, Kester AD, Stoffers HE, et al. 2004. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. *J Clin Epidemiol*, 57:294–300.

Hsia J, Criqui MH, Rodabough RJ, et al; Women’s Health Initiative Investigators. 2004. Estrogen plus progestin and the risk of peripheral arterial disease: the Women’s Health Initiative. *Circulation*, 109:620–6.

Hsia J, Simon JA, Lin F, et al. 2000. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. *Circulation*, 102:2228–32.

Janzon L, Bergqvist D, Boberg J, et al. 1990. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. *J Intern Med*, 227:301–8.

Jensen J, Nilas L, Christiansen C. 1990. Influence of menopause on serum lipids and lipoproteins. *Maturitas*, 12:321–31.

Jonas HA, Kronmal RA, Psaty BM, et al. 1996. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. *CJS Collaborative Research Group. Cardiovascular Health Study*. *Ann Epidemiol*, 6:314–23.

Le Gal G, Gourlet V, Hogref P, et al. 2003. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The Vascular Aging (EVA) Study. *Atherosclerosis*, 166:163–70.

Lewis MA, Spitzer WO, Heinemann LA, et al. 1996. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. *Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ*, 312:88–90.

Lonn E, Roccaforte R, Yi Q, et al; HOPE Investigators. Heart Outcomes Prevention Evaluation. 2002. Effect of long-term therapy with ramipril in high-risk women. *J Am Coll Cardiol*, 40:693–702.

Manson JE, Hsia J, Johnson KC, et al; Women’s Health Initiative Investigators. 2003. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med*, 349:523–34.

McDermott MM, Liu K, Greenland P, et al. 2004. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. *JAMA*, 292:453–61.

Meijer WT, Hoes AW, Rutgers D, et al. 1998. Peripheral arterial disease in the elderly. The Rotterdam Study. *Arterioscler Thromb Vasc Biol*, 18:185–92.

Menard JR, Smith HE, Riebe D, et al. 2004. Long-term results of peripheral arterial disease rehabilitation. *J Vasc Surg*, 39:1186–92.

Mohler ER 3rd, Hiatt WR, Creager MA. 2003. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation*, 108:1481–6.
PAD and postmenopausal hormone therapy

Mondillo S, Ballo P, Barbati R, et al. 2003. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. *Am J Med*, 114:359–64.

Murabito JM, Evans JC, Larson MG, et al; Framingham Study. 2003. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. *Arch Intern Med*, 163:1939–42.

Murabito JM, Evans JC, Nieto K, et al. 2002. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. *Am Heart J*, 143:961–5.

Newman AB, Shemanski L, Manolio TA, et al. 1999. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. *Arterioscler Thromb Vasc Biol*, 19:538–45.

O’Hare AM, Glidden DV, Fox CS, et al. 2004. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999–2000. *Circulation*, 109:320–3.

O’Hare AM, Vittinghoff E, Hsia J, et al. 2004. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the heart and estrogen/progestin replacement study (HERS). *J Am Soc Nephrol*, 15:1046–51.

Pedersen TR, Kjekshus J, Pyorala K, et al. 1998. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol*, 81:333–5.

Perloff D, Grim C, Flack J, et al. 1993. Human blood pressure determination by sphygmomanometry. *Circulation*, 88:2460–70.

Raines JK, Farrar J, Noicely K, et al. 2004. Ankle/Brachial index in the primary care setting. *Vasc Endovasc Surg*, 38:131–6.

Rose GA, Blackburn H, Gillum RF, et al. 1982. Cardiovascular survey methods. Geneva: World Health Organization.

Sacks D. 2003. The TransAtlantic Inter-Society Consensus (TASC) on the Management of Peripheral Arterial Disease. *J Vasc Interv Radiol*, 14:S351.

Stewart KJ. 2002. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. *JAMA*, 288:1622–31.

Tsai AW, Folsom AR, Rosamond WD, et al. 2001. Ankle-brachial index and 7-year ischemic stroke incidence. The ARIC Study. *Stroke*, 32:1721–4.

Westendorp IC, in’t Veld BA, Grobbee DE, et al. 2000. Hormone replacement therapy and peripheral arterial disease. The Rotterdam Study. *Arch Intern Med*, 160:2498–502.

The Women’s Health Initiative Steering Committee. Anderson GL, Limacher M, Assaf AR, et al. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative Randomized Controlled Trial. *JAMA*, 291:1701–12.

The Writing Group for the PEPI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA*, 273:199–208.

Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*, 342:145–53.
